Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2020-11-23 Share Issue/Capital Cha…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Simcere Pharmaceutical Group Limited, detailing changes in issued share capital and share buybacks. It includes specific data on share issues, repurchases, and confirmations related to compliance with listing rules. The content focuses on share capital changes and repurchase activities, which aligns with announcements regarding share issues or capital changes. The document is about reporting changes in issued shares and repurchases, not a full financial report or earnings release. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length (8636 characters) and detailed data support it being a substantive disclosure rather than a brief announcement or certification.
2020-11-23 English
VOLUNTARY ANNOUNCEMENT SIM1909-13, A DRUG FOR GOUT WITH HYPERURICEMIA OF SIMCERE PHARMACEUTICAL GROUP LIMITED, OBTAINING CLINICAL IMPLIED APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding a clinical implied approval for a new drug SIM1909-13. It provides business updates about the drug development and regulatory status but does not contain financial statements, audit information, or detailed financial results. It is not a report or transcript but an announcement of a business development event. The document length is 4274 characters, which is relatively short and typical for an announcement. There is no indication of voting results, management changes, or financing updates. Therefore, the document fits best into the category of a Regulatory Filing (RNS), which is a fallback category for miscellaneous announcements that do not fit other specific categories.
2020-11-18 English
PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD
Capital/Financing Update Classification · 95% confidence The document is an announcement related to the partial exercise of an over-allotment option, stabilizing actions, and the end of the stabilization period following a global offering of shares by Simcere Pharmaceutical Group Limited. It details share allotment, share capital changes, use of proceeds, and regulatory compliance with the Hong Kong Stock Exchange listing rules. The document does not contain financial statements or detailed financial performance data, nor is it a transcript, management report, or proxy solicitation. It is a regulatory announcement about capital market activities related to share issuance and stabilization after an IPO. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief report publication announcement or a simple regulatory filing. Confidence is high given the clear focus on share issuance and stabilization activities.
2020-11-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2020
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return of equity issuer on movements in securities for the month ended 31/10/2020, submitted to the Hong Kong Exchanges and Clearing Limited. It includes detailed information on movements in authorized share capital, issued share capital, share options, warrants, convertibles, and other share capital changes. The document is regulatory in nature, reporting on share capital movements and confirmations related to securities issued, consistent with regulatory filing requirements under stock exchange rules. It is not an annual or interim financial report, earnings release, or management discussion. It is not a proxy, AGM material, or legal proceeding. The document is a regulatory compliance filing reporting share capital movements and confirmations to the exchange, fitting the category of Regulatory Filings (RNS). The document length is over 14,000 characters, indicating it is a full filing, not a brief announcement or report publication notice.
2020-11-05 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles and functions, including committee memberships. It does not contain financial data, audit results, or meeting minutes, but rather focuses on the composition and structure of the board and its committees. This matches the description of Board/Management Information filings, which announce changes or details about the company's board or senior management. The document is short and does not indicate it is an announcement of a report publication or a regulatory filing. Therefore, the appropriate classification is MANG (Board/Management Information).
2020-10-23 English
Terms of Reference of the Strategy Committee
Governance Information Classification · 100% confidence The document is titled 'Terms of Reference of the Strategy Committee' and details the composition, duties, meeting procedures, and governance of a board committee. It is a governance-related document outlining internal rules and committee responsibilities rather than financial results, audit information, or shareholder meeting materials. There is no indication of financial data, voting results, or regulatory filings. The content aligns with governance practices and board committee charters. Therefore, the document fits best under Governance Information (CGR). The document length (9207 characters) supports it being a full terms of reference document rather than a brief announcement or notice.
2020-10-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.